{"nctId":"NCT03525574","briefTitle":"A Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy","startDateStruct":{"date":"2018-10-09","type":"ACTUAL"},"conditions":["Cystic Fibrosis"],"count":507,"armGroups":[{"label":"ELX/TEZ/IVA","type":"EXPERIMENTAL","interventionNames":["Drug: ELX/TEZ/IVA","Drug: IVA"]}],"interventions":[{"name":"ELX/TEZ/IVA","otherNames":["VX-445/VX-661/VX-770","elexacaftor/tezacaftor/ivacaftor"]},{"name":"IVA","otherNames":["VX-770","ivacaftor"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Completed study drug treatment in a parent study i.e.VX17-445-102 (NCT03525444) and VX17-445-103 (NCT03525548); or had study drug interruption(s) in a parent study but completed study visits up to the last scheduled visit of the Treatment Period in the parent study.\n\nExclusion Criteria:\n\n* History of drug intolerance in a parent study that would pose an additional risk to the subject in the opinion of the investigator.\n* Current participation in an investigational drug trial (other than a parent study)\n\nOther protocol defined Inclusion/Exclusion criteria may apply.","healthyVolunteers":false,"sex":"ALL","minimumAge":"12 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Treatment Period: Safety and Tolerability as Assessed by Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)","description":null,"paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"504","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"175","spread":null}]}]}]},{"type":"SECONDARY","title":"Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) for 102/105 Efficacy Set","description":"FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. This analysis set included study 102 parent study participants who received Placebo-ELX/TEZ/IVA and ELX/TEZ/IVA-ELX/TEZ/IVA.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15.3","spread":"0.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.8","spread":"0.8"}]}]}]},{"type":"SECONDARY","title":"Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) for 103/105 Efficacy Set","description":"FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. This analysis set included study 103 parent study participants who received TEZ/IVA-ELX/TEZ/IVA and ELX/TEZ/IVA-ELX/TEZ/IVA.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.9","spread":"1.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.7","spread":"1.3"}]}]}]},{"type":"SECONDARY","title":"Absolute Change in Sweat Chloride (SwCl) for 102/105 Efficacy Set","description":"Sweat samples were collected using an approved collection device. This analysis set included study 102 parent study participants who received Placebo-ELX/TEZ/IVA and ELX/TEZ/IVA-ELX/TEZ/IVA.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-47.0","spread":"1.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-45.3","spread":"1.6"}]}]}]},{"type":"SECONDARY","title":"Absolute Change in Sweat Chloride (SwCl) for 103/105 Efficacy Set","description":"Sweat samples were collected using an approved collection device. This analysis set included study 103 parent study participants who received TEZ/IVA-ELX/TEZ/IVA and ELX/TEZ/IVA-ELX/TEZ/IVA.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-48.2","spread":"3.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-48.2","spread":"3.5"}]}]}]},{"type":"SECONDARY","title":"Number of Pulmonary Exacerbations (PEx) for 102/105 Efficacy Set","description":"Pulmonary exacerbation was defined as the treatment with new or changed antibiotic therapy (intravenous, inhaled, or oral) for greater than or equal to 4 sinopulmonary signs/symptoms.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"174","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Pulmonary Exacerbations (PEx) for 103/105 Efficacy Set","description":"Pulmonary exacerbation was defined as the treatment with new or changed antibiotic therapy (intravenous, inhaled, or oral) for greater than or equal to 4 sinopulmonary signs/symptoms.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"43","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to First PEx for 102/105 Efficacy Set","description":"Time-to-first pulmonary exacerbation was analyzed using Kaplan-Meier estimates and expressed in terms of event-free probability. PEx was defined as the treatment with new or changed antibiotic therapy (intravenous, inhaled, or oral) for greater than or equal to 4 sinopulmonary signs/symptoms.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to First PEx for 103/105 Efficacy Set","description":"Time-to-first pulmonary exacerbation was analyzed using Kaplan-Meier estimates and expressed in terms of event-free probability. PEx was defined as the treatment with new or changed antibiotic therapy (intravenous, inhaled, or oral) for greater than or equal to 4 sinopulmonary signs/symptoms.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null}]}]}]},{"type":"SECONDARY","title":"Absolute Change in Body Mass Index (BMI) for 102/105 Efficacy Set","description":"BMI was defined as weight in kilogram (kg) divided by height in square meter (m\\^2).This analysis set included study 102 parent study participants who received Placebo-ELX/TEZ/IVA and ELX/TEZ/IVA-ELX/TEZ/IVA.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.81","spread":"0.16"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.74","spread":"0.16"}]}]}]},{"type":"SECONDARY","title":"Absolute Change in Body Mass Index (BMI) for 103/105 Efficacy Set","description":"BMI was defined as weight in kilogram (kg) divided by height in square meter (m\\^2).This analysis set included study 103 parent study participants who received TEZ/IVA-ELX/TEZ/IVA and ELX/TEZ/IVA-ELX/TEZ/IVA.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.72","spread":"0.24"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.85","spread":"0.22"}]}]}]},{"type":"SECONDARY","title":"Absolute Change in BMI Z-score for 102/105 Efficacy Set","description":"BMI was defined as weight in kg divided by height in m\\^2. Z-score is a statistical measure to describe whether a mean was above or below the standard. BMI, adjusted for age and sex, was analyzed as BMI-for-age z-score. A z-score of 0 is equal to the mean and is considered normal. Lower numbers indicate values lower than the mean and higher numbers indicate values higher than the mean. Higher values are indicative of higher BMI. This analysis set included study 102 parent study participants who received Placebo-ELX/TEZ/IVA and ELX/TEZ/IVA-ELX/TEZ/IVA.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.24","spread":"0.09"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.18","spread":"0.09"}]}]}]},{"type":"SECONDARY","title":"Absolute Change in BMI Z-score for 103/105 Efficacy Set","description":"BMI was defined as weight in kg divided by height in m\\^2. Z-score is a statistical measure to describe whether a mean was above or below the standard. BMI, adjusted for age and sex, was analyzed as BMI-for-age z-score. A z-score of 0 is equal to the mean and is considered normal. Lower numbers indicate values lower than the mean and higher numbers indicate values higher than the mean. Higher values are indicative of higher BMI. This analysis set included study 103 parent study participants who received TEZ/IVA-ELX/TEZ/IVA and ELX/TEZ/IVA-ELX/TEZ/IVA.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.36","spread":"0.14"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.24","spread":"0.15"}]}]}]},{"type":"SECONDARY","title":"Absolute Change in Body Weight for 102/105 Efficacy Set","description":"This analysis set included study 102 parent study participants who received Placebo-ELX/TEZ/IVA and ELX/TEZ/IVA-ELX/TEZ/IVA.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.6","spread":"0.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.0","spread":"0.5"}]}]}]},{"type":"SECONDARY","title":"Absolute Change in Body Weight for 103/105 Efficacy Set","description":"This analysis set included study 103 parent study participants who received TEZ/IVA and ELX/TEZ/IVA.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.1","spread":"0.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.3","spread":"0.7"}]}]}]},{"type":"SECONDARY","title":"Absolute Change From Baseline in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score for 102/105 Efficacy Set","description":"The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms, score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life. This analysis set included study 102 parent study participants who received Placebo-ELX/TEZ/IVA and ELX/TEZ/IVA-ELX/TEZ/IVA.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15.3","spread":"1.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.3","spread":"1.5"}]}]}]},{"type":"SECONDARY","title":"Absolute Change From Baseline in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score for 103/105 Efficacy Set","description":"The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms, score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life. This analysis set included study 103 parent study participants who received TEZ/IVA and ELX/TEZ/IVA.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.8","spread":"2.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.6","spread":"2.4"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":175,"n":506},"commonTop":["Cough","Infective pulmonary exacerbation of cystic fibrosis","Headache","COVID-19","Oropharyngeal pain"]}}}